HEADER RIBOSOME 16-JAN-04 1S4J TITLE NMR STRUCTURE OF CROSS-REACTIVE PEPTIDES FROM HOMO SAPIENS COMPND MOL_ID: 1; COMPND 2 MOLECULE: 60S ACIDIC RIBOSOMAL PROTEIN P2; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: H13 - C-TERMINAL DOMAIN; COMPND 5 SYNONYM: RIBOSOMAL P2 PROTEIN; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 OTHER_DETAILS: PEPTIDE OBTAINED BY SOLID PHASE SYNTHESIS. SOURCE 4 THE SEQUENCE IS NATURALLY FOUND IN HOMO SAPIENS KEYWDS ANTIGENIC PEPTIDE, RIBOSOMAL P2 PROTEIN, CHAGAS DISEASE, KEYWDS 2 RIBOSOME EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR M.R.SOARES,P.M.BISCH,A.C.CAMPOS DE CARVALHO,A.P.VALENTE, AUTHOR 2 F.C.L.ALMEIDA REVDAT 2 24-FEB-09 1S4J 1 VERSN REVDAT 1 16-MAR-04 1S4J 0 JRNL AUTH M.R.SOARES,P.M.BISCH,A.C.CAMPOS DE CARVALHO, JRNL AUTH 2 A.P.VALENTE,F.C.L.ALMEIDA JRNL TITL CORRELATION BETWEEN CONFORMATION AND ANTIBODY JRNL TITL 2 BINDING: NMR STRUCTURE OF CROSS-REACTIVE PEPTIDES JRNL TITL 3 FROM T. CRUZI, HUMAN AND L. BRAZILIENSIS JRNL REF FEBS LETT. V. 560 134 2004 JRNL REFN ISSN 0014-5793 JRNL PMID 14988012 JRNL DOI 10.1016/S0014-5793(04)00088-2 REMARK 1 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1S4J COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 21-JAN-04. REMARK 100 THE RCSB ID CODE IS RCSB021357. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 278 REMARK 210 PH : 5.5 REMARK 210 IONIC STRENGTH : 10MM PHOSPHATE BUFFER REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 2MM OF PEPTIDE; 10% D2O; 10MM REMARK 210 PHOSPHATE BUFFER AT PH 5.5 REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D NOESY, 2D TOCSY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ, 400 MHZ REMARK 210 SPECTROMETER MODEL : DRX REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NMRPIPE 2.1, NMRVIEW 5.03, REMARK 210 CNS 1.1 REMARK 210 METHOD USED : TORSION ANGLE DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LOWEST REMARK 210 ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: THIS STRUCTURE WAS DETERMINED USING STANDARD 2D REMARK 210 HOMONUCLEAR TECHNIQUES. REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 GLU A 2 -68.13 -126.01 REMARK 500 1 SER A 3 10.82 55.53 REMARK 500 1 ASP A 5 -69.03 -129.10 REMARK 500 1 ASP A 6 -48.27 -146.19 REMARK 500 2 GLU A 2 -70.05 -95.80 REMARK 500 2 SER A 3 8.44 53.47 REMARK 500 2 ASP A 5 -64.27 -129.82 REMARK 500 2 ASP A 6 -56.87 -144.04 REMARK 500 2 PHE A 9 -92.35 -90.05 REMARK 500 3 GLU A 2 -71.12 -94.27 REMARK 500 3 SER A 3 8.31 53.05 REMARK 500 3 ASP A 5 -64.57 -129.56 REMARK 500 3 ASP A 6 -53.88 -146.40 REMARK 500 3 PHE A 9 -81.36 -89.95 REMARK 500 4 SER A 3 17.20 57.51 REMARK 500 4 ASP A 5 -62.12 -126.02 REMARK 500 4 ASP A 6 -50.80 -153.24 REMARK 500 4 PHE A 9 -78.74 -83.46 REMARK 500 5 GLU A 2 -68.74 -95.18 REMARK 500 5 SER A 3 8.69 53.31 REMARK 500 5 ASP A 5 -64.01 -129.75 REMARK 500 5 ASP A 6 -57.42 -143.95 REMARK 500 5 PHE A 9 -92.45 -89.54 REMARK 500 6 SER A 3 9.70 54.00 REMARK 500 6 ASP A 5 -63.41 -129.11 REMARK 500 6 ASP A 6 -58.21 -144.31 REMARK 500 6 PHE A 9 -97.69 -89.40 REMARK 500 7 SER A 3 9.36 53.81 REMARK 500 7 ASP A 5 -62.92 -129.21 REMARK 500 7 ASP A 6 -58.49 -144.52 REMARK 500 7 PHE A 9 -93.23 -90.37 REMARK 500 8 GLU A 2 -68.00 -95.92 REMARK 500 8 SER A 3 8.97 53.76 REMARK 500 8 ASP A 5 -63.84 -129.21 REMARK 500 8 ASP A 6 -57.79 -143.96 REMARK 500 8 PHE A 9 -96.83 -89.32 REMARK 500 9 GLU A 2 -71.06 -126.92 REMARK 500 9 SER A 3 9.25 55.05 REMARK 500 9 ASP A 5 -70.72 -130.15 REMARK 500 9 ASP A 6 -44.69 -146.81 REMARK 500 9 PHE A 9 -159.56 -90.98 REMARK 500 9 LEU A 11 -18.97 74.92 REMARK 500 10 GLU A 2 -72.11 -106.87 REMARK 500 10 SER A 3 12.15 54.77 REMARK 500 10 ASP A 5 -64.17 -126.31 REMARK 500 10 ASP A 6 -53.71 -148.91 REMARK 500 10 MET A 7 -157.74 -138.02 REMARK 500 10 PHE A 9 -159.12 -91.92 REMARK 500 11 GLU A 2 -75.56 -116.45 REMARK 500 11 SER A 3 9.31 52.59 REMARK 500 11 ASP A 5 -64.27 -128.49 REMARK 500 11 ASP A 6 -61.84 -145.22 REMARK 500 11 PHE A 9 -87.78 -94.00 REMARK 500 12 GLU A 2 -73.16 -127.19 REMARK 500 12 SER A 3 1.81 56.47 REMARK 500 12 ASP A 5 -73.85 -139.85 REMARK 500 12 MET A 7 -170.08 63.87 REMARK 500 13 SER A 3 167.47 55.36 REMARK 500 13 ASP A 4 13.08 44.28 REMARK 500 13 ASP A 5 -77.24 -100.75 REMARK 500 14 GLU A 2 -70.35 -130.12 REMARK 500 14 SER A 3 10.05 54.56 REMARK 500 14 ASP A 5 -66.87 -130.58 REMARK 500 14 ASP A 6 -59.60 -147.97 REMARK 500 14 PHE A 9 -159.21 -92.52 REMARK 500 14 LEU A 11 -19.08 74.82 REMARK 500 15 SER A 3 9.51 53.81 REMARK 500 15 ASP A 5 -63.40 -129.36 REMARK 500 15 ASP A 6 -57.87 -144.62 REMARK 500 15 PHE A 9 -93.27 -89.89 REMARK 500 16 GLU A 2 -72.27 -93.69 REMARK 500 16 SER A 3 8.71 53.32 REMARK 500 16 ASP A 5 -65.06 -129.32 REMARK 500 16 ASP A 6 -55.88 -147.09 REMARK 500 16 PHE A 9 -75.43 -89.60 REMARK 500 17 GLU A 2 -70.10 -95.87 REMARK 500 17 SER A 3 8.87 53.74 REMARK 500 17 ASP A 5 -64.32 -129.32 REMARK 500 17 ASP A 6 -57.96 -143.67 REMARK 500 17 PHE A 9 -94.71 -89.21 REMARK 500 18 GLU A 2 -65.78 -98.07 REMARK 500 18 SER A 3 1.69 55.43 REMARK 500 18 ASP A 5 -71.27 -138.00 REMARK 500 18 ASP A 6 86.66 -156.40 REMARK 500 18 MET A 7 -171.40 63.99 REMARK 500 18 PHE A 9 -102.78 -88.36 REMARK 500 19 GLU A 2 -67.44 -98.48 REMARK 500 19 SER A 3 2.81 55.61 REMARK 500 19 ASP A 5 -72.86 -138.46 REMARK 500 19 ASP A 6 84.88 -154.98 REMARK 500 19 MET A 7 -166.66 64.25 REMARK 500 19 PHE A 9 -107.69 -88.23 REMARK 500 20 SER A 3 11.56 54.45 REMARK 500 20 ASP A 5 -62.62 -128.00 REMARK 500 20 ASP A 6 -57.28 -146.47 REMARK 500 20 PHE A 9 -101.30 -92.90 REMARK 500 20 LEU A 11 -63.98 75.16 REMARK 500 20 PHE A 12 -80.56 31.42 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1S4H RELATED DB: PDB REMARK 900 C-TERMINUS PEPTIDE OF RIBOSAMAL P2 PROTEIN FROM L. REMARK 900 BRASILIENSIS DBREF 1S4J A 1 13 UNP P05387 RLA2_HUMAN 103 115 SEQRES 1 A 13 GLU GLU SER ASP ASP ASP MET GLY PHE GLY LEU PHE ASP CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL MASTER 169 0 0 0 0 0 0 6 0 0 0 1 END